



ENGLISH TRANSLATION OF JAPANESE-LANGUAGE DOCUMENT

This is a translation of the original Japanese-language document and is provided for convenience only. In the event of any discrepancy between this translated document and Japanese original, the original shall prevail.

## PRESS RELEASE

For Immediate Release

February 25<sup>th</sup>, 2022

### **GE Healthcare Pharma and Taiyo Pharma Tech Signs a Contract Manufacturing Agreement to Manufacture Contrast Media\* Used for Diagnostic Imaging, and Full-scale Operation Starts on March 3<sup>rd</sup>**

On December 21, 2021, GE Healthcare Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo, President & Representative Director, GE Healthcare Pharma Limited / General Manager, Pharmaceutical Diagnostics Korea&Japan region, GE Healthcare: Masaki Wakabayashi; hereinafter, GE Healthcare Pharma) and TAIYO Pharma Tech Co., Ltd. (Headquarter: Takatsuki-City, Osaka, President and CEO: Eiji Sato; hereinafter, Taiyo Pharma Tech) signed a Contract Manufacturing Agreement for the manufacturing of Contrast Media\* used for diagnostic imaging. The Contract will become effective from March 3<sup>rd</sup>, 2022, at which point Taiyo Pharma Tech will begin manufacturing the contrast agents at the Takatsuki Plant on behalf of GE Healthcare Pharma, the Market Authorization Holder for the products.

Contrast Media\*: Omnipaque® Non-ionic X-ray contrast media, Visipaque® Non-ionic isoosmolar X-ray contrast media, Omniscan® Linear Non-ionic MRI contrast media, Sonazoid® Ultrasound diagnostic contrast media

In March 2020, GE Healthcare Pharma inherited the manufacturing and marketing approval of the four Contrast Media\* which had been manufactured and sold in Japan by Daiichi-Sankyo Co., Ltd. (Headquarter: Chuo-ku, Tokyo). GE Healthcare Pharma belongs to GE Healthcare Diagnostics Division, which is an innovator in medical technology and diagnostics as part of GE Healthcare with 50,000 employees worldwide. GE Healthcare's Contrast Media are provided in more than 130 countries and territories.



Through the Contract Manufacturing Agreement with Taiyo Pharma Tech, GE Healthcare Pharma will secure a highly reliable domestic manufacturing site and build a foundation for long-term commitment to the Japanese market and stable supply. We intend to continue to provide innovation in diagnostic imaging through the introduction of new products and other means, which will lead to further business expansion.

Masaki Wakabayashi, President & Representative Director, GE Healthcare Pharma Limited / General Manager, Pharmaceutical Diagnostics Korea&Japan Region, GE Healthcare, said, "The conclusion of the Contract Manufacturing Agreement with Taiyo Pharma Tech is a major milestone for achieving our vision of contributing to "Precision Health" through innovation in diagnostic imaging. The stable supply of high-quality products is a lifeline for pharmaceutical manufacturers, and we believe that the partnership with Taiyo Pharma Tech, which has been in operation for a long time since the time it belonged to Daiichi Sankyo Group, will be a great asset for our company to be able to commit to the Japanese market that demands to meet high quality requirements. As a partner of medical professionals involved in diagnostic imaging, GE Healthcare Pharma will continue to contribute to patient's health through improved diagnostic imaging technologies".

Taiyo Pharma Tech has been producing the Contrast Media\* as Daiichi Sankyo Group, and from October 2019 as a group company of Taiyo Holding Co., Ltd. at its main base, Takatsuki Plant (Takatsuki-shi, Osaka Prefecture), and continuing to maintain and develop manufacturing technologies and systems. The long term Contract Manufacturing Agreement with GE Healthcare Pharma will be an important foundation for our business in the field of injection formulation manufacturing, which is the main business of Taiyo Pharma Tech.

In addition, Taiyo Pharma Tech aims to increase international transactions and expand its business overseas as a growth strategy for its contract pharmaceutical manufacturing business. The conclusion of this contract with a global mega pharma company will be a major step towards achieving this goal. Through this contract, we hope to strengthen our organization and technical/business capabilities, leading to further expansion of our business.

Suguru Ominato, Executive Vice President & Representative Director, General Manager of Sales Department, TAIYO Pharma Tech Co. Ltd., said, "This is a major step for our company to be able to conclude the Contract Manufacturing Agreement with GE Healthcare Pharma when aiming to expand our contract pharmaceutical



manufacturing business both domestically and overseas. We are confident that this contract will be the best and strongest partnership for GE Healthcare Pharma to promote technological innovation in the field of diagnostic imaging, which they are aiming for in the future. The Contrast Media\* will be manufactured in Takatsuki Plant which we have continued to cultivate and improve the manufacturing technologies, facilities, and organization since the time when we were under Daiichi Sankyo Group. Taiyo Pharma Tech will continue to be the best partner for GE Healthcare Pharma, while at the same time developing and introducing new technologies to meet the diverse needs of domestic and overseas pharmaceutical companies."

---

(company information)

### **About GE Healthcare Pharma Co., Ltd.**

GE Healthcare Pharma is working to deliver high-quality and accurate diagnostic technologies through contrast media to patients in Japan, based on GE Healthcare's global strategy of leading innovators in diagnostic technology to achieve the "Precision Health". We will inherit the know-hows accumulated by Daiichi Sankyo Co., Ltd. over more than 30 years since the launch of Omnipaque® sales and contribute to the diagnostic imaging field.

For more information, see <https://www.gehealthcare.co.jp/products/pharma> of the website.

For inquiries, please contact: GE Healthcare Pharma TEL 0120-241-454 (Medical Information Center)

### **TAIYO Pharma Tech Co.,Ltd**

In October 2019, Taiyo Pharma Tech began operations as a group company of TAIYO Holdings Co., Ltd. (Headquarter: Toshima-ku, Tokyo; President and Representative Director: Eiji Sato; Securities Code: 4626). The main base, Takatsuki Plant started its operation in December 1933 and has been the main plant in the western part of



Japan of Daiichi Sankyo Group for more than 85 years. After becoming part of TAIYO Holdings in 2019, the company has continued to operate as a contract manufacturer of pharmaceuticals with Takatsuki Plant at its core, mainly producing the solid and injection formulations of Daiichi Sankyo Co., Ltd., maintaining its high-quality and stable production under sophisticated GMP control, and increased cost competitiveness. We are also introducing and developing technologies to address the contract manufacturing of new modalities, including regenerative medicine and gene therapy.

See <https://www.taiyo-pt.co.jp/> on the website for more information.

For inquiries, please contact: Taiyo Pharma Tech Co., Ltd. TEL 072-682-1181 (Representative)



The picture shows the closure on December 21, 2021.

Right: President & Representative Director, GE Healthcare Pharma Limited /  
General Manager, Pharmaceutical Diagnostics Korea&Japan region, GE  
Healthcare  
Masaki Wakabayashi

Left: Executive Vice President & Representative Director, General Manager of  
Sales Department, Taiyo Pharma Tech Co., Ltd.  
Suguru Ominato